Lab21 is expanding its clinical diagnostics portfolio with the introduction of a new service to identify the two most common causes of fungal pneumonia. The CE-marked FXGTM:RESP (ASP+) test, developed by UK diagnostics company Myconostica, will identify infections caused by Aspergillus and Pneumocystis, which account for over 95% of cases of fungal pneumonia and could radically alter the diagnosis of fungal disease.
UK NEQAS IMPROVES PATIENT CARE
We aim to improve patient care through monitoring the quality of tests and their reporting, in an independent manner and on a not-for-profit basis.
We are here to help ensure optimal quality in testing for the benefit of patients.
We believe that the result of tests should be:
Hilton Birmingham Metropole Hotel, B40 1P
11 July 2025
Online
15-16 July, 2025
online
7 August, 2025
UK NEQAS CPT, The Haylofts, Newcastle
13 August, 2025
ACV, Vienna, Austria
6 -10 September, 2025
